Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Invivyd Q4 2025 Earnings Call - DECLARATION Hits Enrollment, IDMC Clears Broader Enrollment; Mid-2026 Readout Intact
Invivyd reported that its DECLARATION trial for VYD2311 has reached target enrollment, with early event accrual and a safety review from the Independent Data Monitoring Committee that relaxed enrollme...
- DECLARATION trial for VYD2311 has reached target enrollment, randomized approximately 1,770 subjects in a 1:1:1 two active arms plus placebo design.
- The Independent Data Monitoring Committee reviewed unblinded safety data and recommended: allow pregnant and breastfeeding women to enroll, remove contraception requirement for women of childbearing potential, and drop prespecified safety visits at days 8, 38, and 68 post-dose.
- Management reports event accumulation in DECLARATION is underway and on track, but community attack rates remain an external variable that could change outcomes and timing.
- +12 more takeaways
Brilliant Earth Q4 2025 Earnings Call - Record Quarter, Fine Jewelry Breakout, Profitable Despite Soaring Metal Costs
Brilliant Earth closed 2025 with its largest quarter ever, posting Q4 net sales of $124.4 million (+4.1% YoY) and full-year sales of $437.5 million (+3.6%). The big story is a breakout in fine jewelry...
- Q4 net sales $124.4 million, up 4.1% YoY, the largest quarter in company history.
- Full-year 2025 net sales $437.5 million, up 3.6% YoY.
- Q4 gross margin 55.9%, full-year gross margin 57.5%, both down significantly year-over-year (Q4 down ~370 bps).
- +13 more takeaways
Ranpak Holdings Fourth Quarter 2025 Earnings Call - Automation and North America e-commerce power growth, Europe and warrant charges weigh on margins
Ranpak closed 2025 with clear momentum in automation and North America e-commerce, while Europe softened and non-cash warrant accounting trimmed results. Automation delivered its biggest year yet, vol...
- Q4 consolidated net revenue rose 2.2% on a constant currency basis, or 4.4% excluding a $5 million warrant-related headwind.
- Automation was the standout, growing nearly 40% in Q4 on a constant currency basis and 34.4% for full year 2025, finishing the year with the strongest order book in company history.
- North America drove performance, with Q4 volume up 5.5% and full-year volume up 14.3%, led by strong e-commerce holiday demand and enterprise account wins.
- +11 more takeaways
Ambiq Micro Q4 2025 Earnings Call - Management Sees Path to >$100M in 2026 Backed by Apollo5 Momentum and Atomic Roadmap
Ambiq closed 2025 with its strongest quarter and a sharpened focus on Edge AI. Q4 net sales beat guidance as customers accelerated orders, driven by broader adoption of Apollo5 and new product ramps. ...
- Q4 2025 net sales were $20.7 million, up 2% year-over-year, and above company guidance.
- Q4 non-GAAP gross profit was $9.4 million, with a non-GAAP gross margin of 45.5%, roughly 20 percentage points higher year-over-year.
- Full-year 2025 gross profit dollars rose 32.1% despite net sales being down 4.7% year-over-year, validating the company’s strategic repositioning.
- +12 more takeaways
NCS Multistage Fourth Quarter and Full Year 2025 Earnings Call - ResMetrics deal boosts diagnostics, >70% EBITDA-to-cash conversion
NCS Multistage closed 2025 with solid top-line gains and an unusually high cash conversion rate. Full-year revenue rose 13% to $183.6 million (10% ex-ResMetrics), adjusted EBITDA jumped 20% to $26.7 m...
- Full-year 2025 revenue $183.6 million, up 13% year-over-year, and up 10% excluding the ResMetrics acquisition completed July 31, 2025.
- Adjusted EBITDA for 2025 rose 20% to $26.7 million, with management citing expanded operating leverage and product mix improvements.
- Free cash flow after distributions to non-controlling interests was about $19 million in 2025, implying more than 70% conversion of adjusted EBITDA, a standout metric for an asset-light business.
- +13 more takeaways
Capital Clean Energy Carriers Corp. Q4 2025 Earnings Call - Aggressive gas pivot, 3 new LNG high-tech orders and a geopolitically driven spike in spot rates
Capital Clean Energy Carriers used Q4 to double down on its pivot from containers to gas, contracting three latest-technology LNG carriers and delivering the industry first 22,000 cbm liquid CO2 multi...
- Contracted three latest-technology LNG carriers at HD Hyundai Samho, deliveries scheduled one in Q4 2028 and two in Q1 2029, designed for higher fuel efficiency, lower boil-off and enhanced liquefaction capacity.
- Delivered the Active, the world’s first 22,000 cbm liquid CO2 multi-gas carrier, now employed on a six-month LPG charter with an option to extend, demonstrating immediate commercial demand.
- Company has sold 14 container vessels in 24 months, leaving one container vessel on a long-term charter to 2033 with extension options to 2039, management will only sell if accretive.
- +12 more takeaways
NACCO Industries Fourth Quarter 2025 Earnings Call - 59% Adjusted EBITDA Lift, Pension Settlement Produces Net Loss
NACCO closed 2025 with a clear operational rebound, reporting consolidated Adjusted EBITDA up 59% year over year to $14.3 million and consolidated gross profit rising 42% to $12 million on revenue of ...
- Adjusted EBITDA jumped 59% year over year to $14.3 million in Q4 2025, signaling a strong operational recovery across the company.
- Consolidated gross profit rose 42% year over year to $12.0 million, while revenues increased only 5% to $66.8 million, showing margin-driven improvement.
- GAAP net loss of $3.8 million in Q4 was driven by a $7.8 million non-cash pension settlement charge, $6.0 million after tax, plus a full-year tax true-up.
- +12 more takeaways
Aquestive Therapeutics Q4 2025 Earnings Call - Targets Q3 2026 NDA Resubmission for Anaphylm After FDA Type A Request
Aquestive presented a confident, operationally focused update: management has requested a Type A meeting with the FDA (expected within ~30 days), selected CROs and drafted protocols for the two studie...
- Aquestive has submitted a Type A meeting request to the FDA and expects the meeting within ~30 days, following the CRL focused on human factors and a PK study.
- Management is guiding a resubmission of the Anaphylm NDA in Q3 2026, saying they have a "clear and achievable" path to satisfy FDA requests.
- The company has selected CROs and drafted protocols for the two FDA-requested studies, the human factors validation study and a PK study, and is already preparing for dosing.
- +13 more takeaways
CorMedix Q4 2025 Earnings Call - DefenCath guidance affirmed as TDAPA shifts to bundled add-on, REZZAYO Phase 3 readout set for Q2 2026
CorMedix closed a transformational 2025: the Melinta acquisition closed in August, management achieved the targeted $35 million of synergies in Q4, and full-year pro forma revenue reached $401.3 milli...
- CorMedix closed Melinta acquisition in August 2025 and achieved targeted synergies of $35 million during Q4 2025.
- Pro forma full-year 2025 revenue was $401.3 million, in line with prior guidance.
- Q4 2025 net revenue was $128.6 million, with DefenCath contributing $91.2 million and the Melinta portfolio $37.4 million.
- +17 more takeaways
Myers Industries Q4 2025 Earnings Call - Transformation and MTS Divestiture Drive Margin Expansion and FCF Recovery
Myers pitched 2025 as an inflection year. Management executed a focused transformation, exited low‑margin lines and idled two of nine rotational molding facilities, and announced the strategic decisio...
- Q4 net sales were $204.0 million, essentially flat year over year; full year 2025 net sales were $825.7 million, down 1.3% versus 2024.
- Management completed a strategic review and announced the decision to sell Myers Tire Supply, with MTS expected to be treated as discontinued operations beginning in Q1 2026, which will alter future comparability and outlooks for automotive aftermarket exposure.
- Adjusted gross margin in Q4 expanded 140 basis points to 33.6%, and adjusted operating margin widened 230 basis points to 11.0%, reflecting favorable mix, higher volume, and focused transformation savings.
- +11 more takeaways